Libmeldy (Atidarsagene Autotemcel)

Libmeldy is a gene‑therapy product indicated for metachromatic leukodystrophy, a lysosomal storage disorder affecting the central nervous system.

• Late‑infantile metachromatic leukodystrophy: aims to halt disease progression and preserve motor and cognitive function when administered early.
• Juvenile metachromatic leukodystrophy: seeks to stabilize neurological decline and improve quality of life in eligible patients.
• Adult metachromatic leukodystrophy: intended to reduce further neurological deterioration and support functional abilities.

• Atidarsagene autotemcel uses a lentiviral vector to insert a functional ARSA gene into the patient’s autologous CD34+ hematopoietic stem cells. After ex vivo transduction, the modified cells are infused intravenously, where they engraft and produce sustained arylsulfatase A enzyme, decreasing sulfatide accumulation in the central nervous system and mitigating disease pathology.

Libmeldy may be associated with a range of adverse reactions following infusion of genetically modified stem cells.

Common Side Effects

• Infusion‑related reactions such as fever, chills, and nausea.
• Transient fatigue or headache.
• Cytopenias including anemia and thrombocytopenia.
• Mild gastrointestinal upset.
• Transient elevation of liver enzymes.
• Local site discomfort at infusion site.

Serious or Rare Side Effects

• Insertional oncogenesis leading to malignancy.
• Graft failure or poor stem‑cell engraftment.
• Severe infections due to immunosuppression.
• Organ toxicity, including hepatic or renal impairment.
• Neurological complications such as seizures.
• Immune‑mediated reactions including cytokine release syndrome.

Libmeldy requires careful patient selection and monitoring throughout treatment.

• Patient selection: confirm definitive diagnosis of metachromatic leukodystrophy and appropriate disease stage.
• Pre‑infusion conditioning: administer recommended myeloablative or reduced‑intensity chemotherapy as per protocol.
• Monitoring: observe for infusion reactions, hematologic parameters, and organ function during and after administration.
• Infection risk: implement prophylactic antimicrobial measures and avoid live vaccines during immunosuppression.
• Long‑term follow‑up: assess for insertional mutagenesis and secondary malignancies.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Libmeldy may interact with other therapies that affect hematopoiesis or immune function.

Major Interactions (Avoid)

• Myelosuppressive chemotherapy agents: may exacerbate cytopenias.
• Live vaccines: increased risk of severe infection.
• Potent immunosuppressants: could impair stem‑cell engraftment.

Moderate Interactions (Monitor Closely)

• Anticoagulants: monitor for bleeding complications.
• Other gene‑therapy products: avoid overlapping vector exposure.
• CYP enzyme modulators: generally minimal effect but monitor clinical response.